A Phase I/II Study Evaluating The Efficacy OF 5-Azacitidine And Bevacizumab In Advanced Renal Cell Carcinoma.
Phase of Trial: Phase I/II
Latest Information Update: 17 Jun 2017
At a glance
- Drugs Azacitidine (Primary) ; Bevacizumab (Primary)
- Indications Renal cancer
- Focus Adverse reactions
- 09 May 2017 Status changed from active, no longer recruiting to discontinued.
- 01 Sep 2014 According to the ClinicalTrials.gov record, planned end date changed from 1 Jun 2014 to 1 Jun 2015.
- 28 Mar 2013 Planned End Date changed from 1 Mar 2014 to 1 Jun 2014 as reported by ClinicalTrials.gov.